Rachid C. Baz, MD

• Multiple Myeloma 

Dr. Baz has developed a special expertise in managing patients with plasma cell disorders such as multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), plasmacytoma, primary systematic amyloidosis, and Waldenstrom's macroglobulinemia (WM). Dr. Baz is a very active researcher in the field and is involved in a number of clinical trials as well as the Moffitt Myeloma Working Group (MMWG). He is a frequent lecturer on myeloma for both medical and lay audiences. Dr. Baz’s research focuses on malignant hematology and involves the development and implementation of biomarker-driven therapeutics into patient-based phase I and II clinical trials, including early-phase clinical trials in multiple myeloma. In this context, he and his colleagues initiated a clinical trial of a response-adapted therapy in newly diagnosed myeloma patients who are not candidates for high-dose therapy and do not have high-risk disease. He and his team are evaluating several novel agents (novel proteasome inhibitors, novel immunomodulators as well as monoclonal antibodies). Moreover, Dr. Baz has collaborated with outcome researchers (focusing on outcomes to therapy as well as defining optimal sequences of therapy) and with basic scientists (focusing on translational research and new drug development in myeloma).